Maria Krevvata

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 430 citations · Full text

Hematological Malignancy, Overall Survival, Medicine +7

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White et al. · Leukemia · 2020 · 231 citations · Full text

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Alfred L. Garfall, Edward A. Stadtmauer, Wei‐Ting Hwang et al. · JCI Insight · 2018 · 193 citations · Full text

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2021 · 167 citations · Full text

Hematological Malignancy, Medicine, Autologous Stem-cell Transplant +6

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva et al. · Blood · 2021 · 131 citations · Full text